{
  "data": {
    "id": "stat_7X15RJSW8E75N5R0FP14DFMTZ5",
    "url": "https://statorigin.org/stat/stat_7X15RJSW8E75N5R0FP14DFMTZ5",
    "indicator": {
      "slug": "ctgov-glp1-trial-starts",
      "name": "GLP-1, incretin multi-agonist and amylin trial starts",
      "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "CN",
      "name": "China",
      "type": "country"
    },
    "period": {
      "start": "2022-01-01",
      "end": "2022-12-31",
      "type": "year"
    },
    "value": 21,
    "value_text": "21 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China.",
      "quote": "{\"totalCount\":21,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2022). ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_7X15RJSW8E75N5R0FP14DFMTZ5",
      "bibtex": "@misc{clinicaltrialsgo2022ctgovdfmtz5,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China},\n  year         = {2022},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_7X15RJSW8E75N5R0FP14DFMTZ5},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide\\%20OR\\%20tirzepatide\\%20OR\\%20retatrutide\\%20OR\\%20orforglipron\\%20OR\\%20survodutide\\%20OR\\%20cagrilintide\\%20OR\\%20CagriSema\\%20OR\\%20mazdutide\\%20OR\\%20liraglutide\\%20OR\\%20dulaglutide\\%20OR\\%20exenatide\\%20OR\\%20ecnoglutide\\%20OR\\%20danuglipron\\%20OR\\%20pemvidutide\\%20OR\\%20amycretin\\%20OR\\%20efinopegdutide\\%20OR\\%20MariTide\\%20OR\\%20maridebart\\%20OR\\%20petrelintide\\%20OR\\%20\\%22GLP-1\\%20receptor\\%20agonist\\%22\\%20OR\\%20LY3437943\\%20OR\\%20LY3502970\\%20OR\\%20\\%22BI\\%20456906\\%22\\%20OR\\%20LY3298176\\%20OR\\%20IBI362\\%20OR\\%20\\%22AMG\\%20133\\%22\\%20OR\\%20\\%22NNC0487-0111\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2022-01-01\\%2C2022-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22China\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}